Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 08, 2018

SELL
$20.86 - $33.33 $4,672 - $7,465
-224 Closed
0 $0
Q2 2018

Aug 07, 2018

BUY
$25.0 - $27.75 $5,600 - $6,216
224 New
224 $6,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $208M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Catalyst Capital Advisors LLC Portfolio

Follow Catalyst Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalyst Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Catalyst Capital Advisors LLC with notifications on news.